Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly

AbbVie's valuation, in particular, makes it a potentially strong candidate for 2023, while Eli Lilly's growth could support its stock next year.

Time to Buy Eli Lilly (LLY) and AbbVie (ABBV) Stock for 2023?

-  Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive disorder (MDD) with an antidepressant therapy (ADT), showing improvement in symptoms when compared to placebo + ADT -  Designed for specific mood disorders, VRAYLAR is now the first and only dopamine and serotonin partial agonist FDA-approved for the most common forms of depression – as an adjunctive treatment for MDD and the treatment of depressive episodes associated with bipolar I disorder -  About one in five U.S. adults will experience MDD during their lifetime, and many of them may have partial response to the treatment with an ADT NORTH CHICAGO, Ill. , Dec. 16, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR® (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults.

U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder

If approved, linaclotide would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age 1 Submission is based on positive Phase 3 study data demonstrating linaclotide (72mcg) resulted in increases in frequency of spontaneous bowel movements (SBM) and improved stool consistency in children and adolescents aged 6 to 17 years NORTH CHICAGO, Ill. , Dec. 16, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted a supplemental New Drug Application (sNDA) for linaclotide (LINZESS®) to the U.S. Food and Drug Administration (FDA) for the treatment of children and adolescents 6 to 17 years of age with functional constipation (FC).

AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age

Pfizer

Pfizer has a lot more revenue at risk over the next several years than AbbVie does.

Why Pfizer Stock Is Riskier Than AbbVie

Both companies should hurdle their patent cliff concerns.

2 Dividend Stocks That Could Double Your Return in 10 Years

AbbVie Inc is leaving Pharmaceutical Research and Manufacturers of America (PhRMA), the leading U.S. drug industry group said on Thursday.

AbbVie to leave leading U.S. drug industry trade group

Citigroup

Cisco Systems

AT&T

Walgreens

It is almost hard to believe that at this time last year interest rates were still near zero.

Rates Head Higher Again This Week: 5 Value Stocks to Buy Now That Come With Big Dividends

TOKYO and CAMBRIDGE, United Kingdom, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, announces that it has reached an important R&D milestone under its discovery collaboration with AbbVie, the global biopharmaceutical company, focused on inflammatory and autoimmune diseases. The achievement triggers a payment of US$10 million to Sosei Heptares.

Sosei Heptares Receives $10 Million Milestone Payment in Discovery Collaboration with AbbVie Targeting Inflammatory Diseases

AbbVie Ranked #1 in Biotech Sector on the 2022 S&P Corporate Sustainability Assessment NORTH CHICAGO, Ill. , Dec. 12, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that for the tenth consecutive year, it has been named to the Dow Jones Sustainability World Index (DJSI World) and Dow Jones Sustainability North America Index (DJSI North America).

AbbVie Named to Dow Jones Sustainability World Index for 10th Straight Year

Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) follicular lymphoma, previously untreated follicular lymphoma, R/R diffuse large B-cell lymphoma and Richter's syndrome NORTH CHICAGO, Ill. , Dec. 11, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody, alone or in combination for the treatment of patients with relapsed/refractory (R/R) follicular lymphoma (FL), previously untreated FL, R/R diffuse large B-cell lymphoma (DLBCL), as well as Richter's syndrome at the 64th American Society of Hematology (ASH) Annual Meeting.

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas

Alphabet

2022 will soon be in the history books and it's been quite a ride. Tech collapse, inflation, recession: the macro environment looks stressful, but this market definitely has its advantages.

My 2022 Top 3 Picks Year-End Report: VICI Value, AbbVie Profits, Google Decision Time

Exploratory analysis from Cohort 3 of the Phase 2 REFINE study presented in an oral session at ASH NORTH CHICAGO, Ill. , Dec. 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis (MF).

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients

Updated data presented at ASH include CAPTIVATE and GLOW studies and real-world evidence abstracts NORTH CHICAGO, Ill. , Dec. 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new and updated data across clinical and real-world studies in chronic lymphocytic leukemia (CLL).

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Adds to Robust IMBRUVICA® (ibrutinib) Science

Johnson & Johnson

Here are two stocks that investors can count on to deliver increasing dividend payments for many years to come.

2 Ultra-Reliable Dividend Stocks You Can Buy Now and Hold Forever

Kimberly-Clark

Dividend stocks can help investors grow their portfolios in all types of markets.

Have $1,000? 2 Top Dividend Stocks to Buy Right Now

Coca-Cola

These stocks are both beating the market this year.

2 Forever Stocks You Can Buy and Forget About

I am a long-term bull on AbbVie. Its strong Q3 earnings pushed its prices to a near record high.

AbbVie: I Won't Sell Till P/E Reaches 14x

Collaboration leverages HotSpot's Smart Allostery™ drug discovery platform for the development of the first and only small molecule IRF5 (interferon regulatory factor 5) inhibitor for the potential treatment of autoimmune diseases HotSpot to receive an upfront cash payment of $40 million with potential for further milestones and royalties NORTH CHICAGO, Ill. and BOSTON , Dec. 6, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases.

AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline

-- Fifteen abstracts underscore AbbVie's commitment to people living with migraine -- AbbVie to present late-breaking data from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study on neck pain with headache in people with and without migraine -- Results from the PROGRESS Phase 3 trial on atogepant for the preventive treatment of chronic migraine in Europe will also be presented NORTH CHICAGO, Ill. , Dec. 6, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data from its robust migraine portfolio will be presented at the 16th European Headache Federation Congress 2022 (EHC 2022) taking place in Vienna, Austria, December 7-10.

AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress

The Zacks Medical sector has modestly outperformed the S&P 500 over the last three months, up more than 7% vs. the general market's 4% gain.

Relative Strength Found Within These 3 Medical Stocks

The pharma giant's story won't be over with anticipated sales declines for its top-selling drug.

Is AbbVie Stock a Smart Contrarian Pick for 2023?

Amazon

Costco

Etsy

Efforts now could result in gains next year and beyond.

Here's How to Prepare Your Portfolio for 2023

Exelixis

Vertex Pharmaceuticals

3 Stocks to Buy Hand Over Fist in December

Celsius Holdings

Copa Hlds

Equinor

Genmab - ADR

Horizon Pharma

Lattice Semiconductor

Monster Beverage

PepsiCo

Seagen

An array of top stocks in a wide variety of industries are building cup bases as the stock market recovers. The post Top Stocks In Multiple Industries Build Bases As Market Gains Strength appeared first on Investor's Business Daily.

Top Stocks In Multiple Industries Build Bases As Market Gains Strength

Regeneron Pharmaceuticals

Is now a good time to add these biotech stocks to your watchlsit?

News for AbbVie Stock (ABBV)